Abstract OFR-5 Table 1

	N=318
Mean age (years)	66
Sex (female)	166 (52%)
Intestinal metaplasia	60 (19%)
- None	53 (17%)
- Proximal	101 (32%)
- Distal	68 (21%)
- Both locations	36 (11%)
- Present, location unknown	
Only gastric atrophy	60 (19%)
H.pylori present	48 (15%)
Family history of gastric cancer	14 (4%)
- Yes	156 (49%)
- No	148 (47%)
- Unknown	

in countries with a low incidence of gastric cancer. The rate of endoscopic recognition of pre-cancerous lesions, is low. The results of this study suggest that substantial improvement is required in adherence to guidelines for surveillance and endoscopic training in detection of pre-malignant conditions.

Pancreas and neuroendocrine

OTU-17 EXPRESSION, CLINICAL AND PROGNOSTIC VALUE OF DUAL SPECIFIC PROTEIN PHOSPHATASE-7 (DUSP-7) IN PANCREATIC CANCER

¹Yiming Yang*, ¹Andrew J Sanders, ²Chunyi Hao, ²Jiafu Ji, ¹Wen G Jiang. ¹Cardiff University School of Medicine, Cardiff, UK; ²Peking University Cancer Hospital and Institute and Key Laboratory of Carcinogenesis, Beijing, China

10.1136/gutjnl-2021-BSG.23

Introduction Dual Specific Protein Phosphatases (DUSPs) are a family of proteins that dephosphorylate both tyrosine and serine/threonine residues in biological systems and play multiple and diverse role in cells. The clinical impact of the protein phosphatase family has not been well explored in solid tumours. The present study investigated the role of DUSP-7 (also known as PYST2), a protein phosphatase that dephosphorylates mitogen activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and p38 which are important regulators of solid tumours and cancer cells, in pancreatic cancer.

Methods Pancreatic cancer tissues from patients who underwent resections were obtained immediately after surgery, stored and subsequently processed for quantitative analyses of DUSP-7 gene transcript. The expression levels were correlated with the survival and pathological parameters of the patients. Human pancreatic cancer cell line, PANC1 was used in creation of a DUSP-7 knockdown (by way of siRNA) cell model and was assessed for the impact of DUSP-7 on the biological functions by various cell based assays.

Results Pancreatic tumour tissues displayed significantly lower levels of DUSP-7 transcript than normal tissues ($p=0.0031$). Kaplan-Meier Survival analysis showed that patients with high levels of DUSP-7 had a significantly longer survival than those with low levels ($p=0.021$ (Mansel-Cox log rank test), mean survival 30.2 months for high levels *vs* 17.0 months for low

levels). This survival benefit was particularly seen in tumours with low levels of Her-2 expression. It is noted that while high grade tumour had low levels of DUSP-7, the same trend was found with TNM tumours of which high TNM tumours had lower DUSP-7. Tumours with metastatic lymph nodes had marginally higher levels of DUSP-7 than node negative tumours. The presence of microvascular embolism ($p=0.015$) and levels of DUSP-7 ($p=0.044$) were two prognostic indicators of the patients. Knocking down DUSP-7 from PANC1 cancer cells rendered the cell to be less mobile and less adhesive as assessed by way of electric cell-substrate impedance sensing (ECIS).

Conclusions Dual Specific Protein Phosphatase, DUSP7/PYST2 is aberrantly expressed in pancreatic cancer and is a positive survival indicator of the patients.

OTU-18 SILENCE OF THE LAMS: REDUCING RISK IN EUS GUIDED DRAINAGE OF PANCREATIC FLUID COLLECTIONS

Megha Bhandari*, Puneet Chhabra, Matthew Stammers, Nadeem Tehami, Ben Maher. University Hospital Southampton NHS Foundation Trust, Southampton, UK

10.1136/gutjnl-2021-BSG.24

Introduction and Aims Endoscopic ultrasound guided transmural drainage (ETD) followed by endoscopic transluminal necrosectomy (ETN) is the evidence based preferred modality of treatment for symptomatic pancreatic fluid collections (PFC). EUS guided insertion of a lumen apposing metal stent (LAMS) facilitates improved drainage of fluid and improves efficacy of ETN. There is recognised risk associated with the procedure, primarily including bleeding, stent displacement and buried stent. Recent ESGE guidelines on the management of acute necrotising pancreatitis describe the use of imaging prior to drainage and at a 4 week interval, primarily to quantify the solid component in the collection. No definitive imaging protocols are established. In our institution, a protocol was developed to reduce the risk of adverse events associated with drainage. This included pre-intervention arterial phase CT and if identified, prophylactic embolisation of underlying pseudoaneurysm. In addition, all patients underwent CT at 4-5 weeks post stent insertion to determine efficacy of drainage and quantify residual component to determine benefit of long term plastic stents. We sought to assess the impact of the protocol on reducing LAMS associated adverse events.

Methods We evaluated our practice over a two year period between November 2018 and 2020. Prospectively collected data was reviewed retrospectively for the rates of technical success, clinical success and adverse event.

Results A total of 56 ETD procedures were performed on 52 patients. The majority of patients in the cohort were male (70.6%) with a mean age of 58 years. All patients underwent an arterial phase CT prior to ETD. Nine patients (17.3%) required embolisation of a previously unrecognised pseudoaneurysm prior to ETD. All procedures were technically successful (100%). Thirty five (67.3%) patients underwent a single ETN and 10 (19.2%) had multiple ETN procedures. Twenty two (62.8%) patients had a 20mm lumen diameter stent inserted and the remainder 15mm. Forty eight patients (92%) achieved complete resolution of collection with a single stent. Four patients (8%) required either an additional stent (multi-gated approach) or additional percutaneous drain. Stent dislodgement occurred in 4 (7.6%) patients during ETN. The